Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me” [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
Mad Money recap as he provided top stock insights . Answering a caller's query about the stock, Cramer said: Too risky for me. I just think that at this stage, with this market, that one you could lose too much money. I'm very sorry. A laptop and a computer monitor display a detailed stock market technical analysis chart. Photo by Jakub Zerdzicki on Pexels Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for women's cancers. The company reported its Q4 2025 and full-year earnings on March 16. It posted Q4 GAAP EPS of -$0.50, exceeding estimates by $0.01. Net loss for FY25 was $162.5 million compared to $129.5 million in the prior year. While we acknowledge the potential of OLMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly fr
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility [Yahoo! Finance]Yahoo! Finance
- Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals (OLMA) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) had its price target raised by JPMorgan Chase & Co. from $55.00 to $58.00. They now have an "overweight" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]Yahoo! Finance
OLMA
Earnings
- 3/16/26 - Beat
OLMA
Sec Filings
- 3/20/26 - Form SCHEDULE
- 3/16/26 - Form 144
- 3/16/26 - Form 144
- OLMA's page on the SEC website